Travoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Travoprost: From Glaucoma / Ocular Hypertension to Visceral Calciphylaxis
One-Sentence Summary
Travoprost is a topical prostaglandin F2α (FP receptor) agonist originally used to lower intraocular pressure in open-angle glaucoma and ocular hypertension. The TxGNN model predicts it may be effective for Visceral Calciphylaxis, but currently no clinical trials and no publications directly support this specific direction — the prediction rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Glaucoma / Ocular Hypertension (topical IOP reduction) — inferred from trial evidence in this pack; formal MOA/indication record is a data gap |
| Predicted New Indication | Visceral Calciphylaxis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not formally available (flagged as a High-severity data gap). Based on information present in the evidence pack, travoprost is a selective FP receptor agonist; its established clinical effect is increasing uveoscleral outflow to reduce intraocular pressure, and its proven efficacy is limited to glaucoma and ocular hypertension.
Visceral calciphylaxis is a distinct disease process involving vascular medial calcification and microthrombosis, typically seen in end-stage renal disease. There is no established pharmacological pathway connecting FP receptor agonism to the calcification/thrombotic cascade underlying calciphylaxis.
The evidence pack’s own mechanistic assessment for this candidate explicitly notes that the connection is not a known biological pathway — the high TxGNN score likely reflects semantic clustering of “vascular disease”-related nodes in the knowledge graph embedding space, rather than a genuine pharmacological relationship. This should be treated as a hypothesis-generating signal only, not as mechanistically substantiated.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
No marketing authorization records are present in the reviewed dataset (Market Status: Not marketed; Total licenses: 0). Travoprost’s marketed formulations elsewhere are ophthalmic solutions for glaucoma/ocular hypertension (e.g., Travatan®/Travatan Z®), referenced only indirectly through clinical trial titles in this pack — no formal license data was available to tabulate here.
Safety Considerations
Please refer to the package insert for safety information. Note that TFDA warning/contraindication data for this candidate is currently an unresolved Blocking data gap, which by itself prevents any progression to a formal safety review (S1) regardless of efficacy evidence.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked predicted indication (visceral calciphylaxis) has zero supporting clinical trials or literature, and the mechanistic rationale itself flags the association as likely a graph-embedding artifact rather than a genuine pharmacological link. Combined with a Blocking-severity gap in TFDA label/safety data, there is no basis to advance this candidate beyond model prediction (L5/S0).
To proceed, the following is needed:
- TFDA (or equivalent regulatory) label data — warnings, contraindications, DDI (Blocking gap, required before any S1 safety screen)
- Confirmed mechanism of action documentation from DrugBank or primary literature
- Preclinical or case-level evidence specifically linking FP receptor agonism to vascular calcification/calciphylaxis pathophysiology
- If pursued, re-evaluate lower-ranked candidates in this pack with actual trial/literature support (e.g., “vascular disease,” “hemangioendothelioma”) — though note those signals were graded low-relevance (mismatched to glaucoma trials) or, in one case, evidence of an adverse effect (uveal effusion) rather than therapeutic benefit, and would also require independent validation before advancing.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.